NEW YORK, December 29, 2025, 2:08 PM ET — Regular session
- Pfizer shares were down about 0.1% in afternoon trading, hovering in the mid-$25 range.
- Investors remain focused on Pfizer’s 2026 outlook and pipeline rebuild, including its push into obesity drugs.
- Broader U.S. stocks were lower in holiday-thinned trade, with tech leading the pullback.
Pfizer shares dipped slightly on Monday, trading down about 0.1% at $25.06 as of 2:08 p.m. ET. The stock has moved between $24.99 and $25.19 in the regular session.
The muted move matters because liquidity is thinning into year-end, leaving defensive names like large drugmakers more sensitive to sector headlines and positioning. Reuters reported trading volumes were expected to be light this week, with U.S. markets shut on Thursday for New Year’s Day.
For Pfizer, the backdrop is still its long-dated reset story: investors are weighing whether its acquisitions and new launches can offset shrinking COVID product sales and patent expirations on older medicines. Pfizer said earlier this month it does not expect to return to revenue growth until 2029.
The broader tape was also soft. Wall Street’s main indexes were lower on Monday as heavyweight technology shares retreated from last week’s rally, Reuters reported.
In health care, the obesity-drug market stayed in focus after Novo Nordisk cut the price of Wegovy in parts of China, according to a Reuters report. The move underscored intensifying competition and the risk that prices come under pressure as rivals crowd in.
Another Reuters report highlighted how GLP-1 weight-loss drugs are increasingly being sold through consumer-facing channels such as telehealth and apps, alongside efforts by Novo Nordisk and Eli Lilly to broaden access. GLP-1s are a class of medicines that mimic a gut hormone to curb appetite and help control blood sugar.
Pfizer is trying to build a position in that market through dealmaking rather than an in-house lead program. The company said it entered an exclusive licensing agreement with China’s YaoPharma to develop and commercialize an experimental weight-management treatment, with $150 million upfront and up to $1.94 billion in milestone payments.
Reuters has also reported Pfizer closed an acquisition of obesity drug developer Metsera, and that it previously discontinued two oral GLP-1 candidates after liver safety concerns. Those setbacks have kept the obesity opportunity a watched risk-reward swing for Pfizer’s longer-term story.
On the fundamentals, Pfizer forecast 2026 revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3.00 per share in mid-December. “Adjusted” figures strip out certain one-time items to show the underlying business, though investors often debate what should be excluded. Reuters+1
That outlook baked in headwinds from falling COVID product sales and “loss of exclusivity” — industry shorthand for patent expiry that opens the door to generics and biosimilars. “This stock is unlikely to break out of its current mid-20s price range until investors are convinced of a growth trajectory,” Bernstein analyst Courtney Breen said in a note at the time. Reuters
The next scheduled catalyst is Pfizer’s February 3 conference call with analysts at 10:00 a.m. EST, when it plans to issue its fourth-quarter and full-year 2025 performance report and provide an update on results.
In the near term, traders are also watching whether the late-December pullback in U.S. stocks deepens as volumes thin. Reuters said minutes from the Federal Reserve’s prior meeting and weekly jobless claims are among the few macro releases on the radar in an otherwise light week for economic data.
